Plain-English translation of NCT06908252 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 4 โ The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This completed trial tested whether oral PrEP (a daily pill that helps prevent HIV infection) could be successfully offered to people who inject drugs through a mobile health clinic. The researchers wanted to find out if this approach was practical and whether people in this community would be interested in using the medication. The study also examined how people felt about their HIV risk and what they thought about this prevention option.
People who inject drugs face a high risk of HIV infection, especially during times when addiction treatment and healthcare services are hard to access. This trial was designed to see if bringing this medication directly to people through a mobile clinic could be a workable way to prevent HIV in this vulnerable population.
Participants who enrolled in this trial received oral PrEP (a daily preventive medication) through visits to a mobile health clinic. The study gathered information about how people perceived their HIV risk and what they thought about receiving this medication through a mobile unit. This was a small pilot program designed to test whether this approach would work in practice before potentially expanding it.
AI-generated summary from trial data ยท Aug 11, 2026 ยท Not medical advice
United States
Sponsor
Duke University
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Enrollment target
~7 participants
Started
September 2025
Primary completion
May 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.